Yesafili

Yesafili (aflibercept) is an intravitreal injection used to treat retinal conditions like wet age-related macular degeneration and diabetic macular edema. This biosimilar offers a cost-effective alternative for eye health support. Suitable for patients requiring vascular endothelial growth factor inhibition. Short-term supply for ongoing treatment plans.

Yesafili (aflibercept) is prescribed to address retinal disorders caused by abnormal blood vessel growth. It helps reduce fluid leakage and swelling in the macula, supporting vision maintenance. Commonly used for wet age-related macular degeneration and diabetic macular edema. Also indicated for macular edema following retinal vein occlusion. Works by blocking VEGF pathways in the eye.

Patients may notice improved or stabilized vision after treatment with Yesafili. Some experience temporary eye discomfort or redness at the injection site. Blurred vision for a few days post-injection is common. Eye floaters or flashes may occur but typically resolve over time. Regular follow-up appointments help monitor progress.

Store unopened vials refrigerated between 2°C and 8°C. Protect from light and avoid freezing. Use within 24 hours of opening if handled aseptically. Discard any unused portion. Inform your healthcare provider of eye infections or recent eye surgeries. Avoid rubbing the eye post-injection to prevent irritation.

No known direct drug interactions with systemic medications. Caution advised with other intravitreal therapies due to additive effects. Concomitant use of anticoagulants may increase bleeding risk in the eye. Alcohol consumption may exacerbate eye dryness or irritation. Always disclose all medications to your healthcare provider before treatment.